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Toward Engineering a Novel Transplantation Site for
Human Pancreatic Islets
Alexandra M. Smink, Marijke M. Faas, and Paul de Vos
Islet transplantation is a promising therapy for treat-ment of type 1 diabetes. A real breakthrough wasreported when the Edmonton protocol was in-troduced in 2000. This protocol induced insulin in-
dependence in diabetic patients for 1 year (1). Although
these clinical islet transplantations demonstrated the ap-
plication of the technique, the long-term function of the islet
grafts was not that successful. After 2 years, less than 50%
of the patients remained insulin independent. Five years
following transplantation, this declined to just 10% (1). In
recent years, some groups demonstrated remarkable prog-
ress in islet transplantation outcomes (2), and experienced
groups have been able to produce insulin independence
after transplantation of islets from a single donor by con-
trolling all known parameters for optimal islet donation (3).
Recently, a number of groups have focused on the iden-
tiﬁcation of factors determining success or failure of islet
grafts. Various signs point to the transplantation site as
a major factor in graft failure. The majority of islet trans-
plantation is currently accomplished by the infusion of islets
into the liver via the portal vein. Several alternative sites were
investigated in animals and humans for efﬁcacy as trans-
plantation sites for islets, but none adequately accommodated
islet engraftment. A rather novel approach that has been in-
vestigated recently is the engineering of an artiﬁcial site by
using biopolymeric scaffolds. These scaffolds facilitate re-
vascularization and allow adequate glucose sensing and in-
sulin release. Recent developments in this area are reviewed
in this article because of their potential clinical application.
CAUSES OF GRAFT FAILURE OF TRANSPLANTED ISLETS
The exact causes of islet graft failure remain to be iden-
tiﬁed, but high metabolic pressure, recurring autoimmu-
nity, and alloimmunity may be the basis of declining graft
function over the long term (2,3). However, a key issue
that cannot be explained by these responses is that the
vast majority of islets are lost in the period shortly after
transplantation (4). Limitations of the liver as a trans-
plantation site have therefore received considerable at-
tention during the past decade. The potential inadequacies
of the liver as a transplantation site for human islets are
discussed below because of their essential role in islet
grafts.
Adequacy of vascularization. Ideally, the transplantation
site should allow rapid vascularization of the tissue in order
to keep the ischemia period between transplantation and
revascularization as short as possible. Studies in rodents
suggest that the liver meets this requirement because rodent
islets in the liver allow rapid restoration of normoglycemia
and adequate control of metabolism (4). There is, however,
a key difference between humans and rodents that might
make extrapolation of these data challenging (Fig. 1). Ro-
dent islets are relatively large in proportion to liver veins.
The size of rodent islets varies between 100 and 350 mm,
while the average liver vein is 500 mm in diameter. Vascu-
larization is proposed to occur by islets, causing local
thrombosis with ischemia and fast tissue repair responses.
Revascularization and integration in the liver parenchyma
are consequences of these responses (4), which take sev-
eral days. In humans, the situation is very different. Islets
are 100–200 mm in size while the average liver vessel is 10
mm. This implies that the islets are small relative to the
vessels. In order to be caught in the liver, the relatively
small human islets have to adhere to blood clots that adhere
to the walls of the liver veins. The resulting process of
remodeling and vascularization occurs much slower in
humans than in rodents (4). A signiﬁcant loss of islets due to
ischemia may be a consequence.
Low oxygen tension in the liver. The ischemia-induced
loss of viable b-cells may be enhanced by low oxygen ten-
sion in the liver parenchyma (Fig. 2) (5). Even in rats where
the process of vascularization is fast, 50% of the islets are
lost due to hypoxia during the posttransplantation avascular
period (6). Another hypoxia-associated threat is that a mi-
croenvironment of hypoxia triggers the innate immune sys-
tem, resulting in the release of inﬂammatory cytokines such
as interferon-g (IFN-g), tumor necrosis factor-a (TNF-a),
and interleukin (IL)-1b. In turn, these damage the islet grafts
(7). And, last but certainly not least, recent insight suggests
that human b-cells under hypoxic conditions may de-
differentiate and undergo an epithelial-to-mesenchymal
transition under the inﬂuence of hypoxia-mediated activa-
tion of hypoxia-inducible factor-1a (HIF-1a) (8). HIF-1a
mediates Twist expression, which contributes to the de-
velopment of progressive ﬁbrosis (8). All these processes
may impair adequate engraftment in the liver, thereby re-
ducing long-term graft success.
Instant blood-mediated inﬂammatory reaction, allo-
reactivity, and autoimmunity in the liver. Many studies
suggest that the instant blood-mediated inﬂammatory re-
action (IBMIR) is responsible for the loss of islets in the
immediate posttransplantation period (9). IBMIR is an im-
mediate thrombotic reaction that occurs after direct contact
between islets and ABO-compatible blood. This reaction is
triggered by islet-derived chemokines and tissue factor (9).
IBMIR involves activation of coagulation and the comple-
ment system, and induces rapid binding of platelets to the
islet surface (Fig. 3). The activated platelets generate a ﬁbrin
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capsule around the islets that results in islet entrapment in
blood clots. Although this may be beneﬁcial for vasculari-
zation, there is also a deleterious process that may be acti-
vated. Activated platelets upregulate P-selectin expression to
attract and interact with neutrophils and monocytes (10).
Thrombin, tissue factor, ﬁbrin, and ﬁbrinogen may directly
affect macrophages. All these interactions catalyze the in-
ﬂammatory reaction (10). Unstressed islets secrete lower
levels of tissue factor and inﬂammatory mediators. The use
of unstressed islets can therefore mitigate the IBMIR. Fur-
ther, the coating of islets with anticoagulation factors such
as heparin, nicotinamide, or statins can circumvent this re-
action (10). However, this may not be enough to prevent an
immune response.
A recent study (11) with freshly isolated human islets
demonstrated expression of a large panel of genes reminis-
cent of cells undergoing a marked nuclear factor-kB (NF-kB)-
dependent proinﬂammatory response. Islets expressed matrix
metallopeptidase 1 (MMP1) and ﬁbronectin 1 (FN1) (Fig. 4).
These factors are involved in tissue remodeling, adhesion,
and cell migration. Furthermore, the proinﬂammatory cyto-
kines IL-1b and IL-8, as well as the chemokines CXCL2, CCL2,
CXCL12, CXCL1, CXCL6, and CCL28 that induce neutrophil
and monocyte recruitment, were expressed. Expression of
these genes was maintained after implantation in mice. Other
studies have shown expression and production of proin-
ﬂammatory mediators post–islet transplantation. These
include macrophage migration inhibitory factor, TNF, and
IFN-g (12). This may have long-term consequences for
islet survival because there is a correlation between mono-
cyte chemoattractant protein-1 (MCP-1) expression and hu-
man posttransplant outcomes (13). In addition, islets express
ATF3, a transcription factor involved in b-cell apoptosis (11).
Together, these data demonstrate substantial involvement of
the innate immune system in islet graft failure.
Many of the islet-derived cytokines and chemokines also
have chemotactic effects on the innate immunity in the liver.
Natural killer T (NKT) cells, monocytes, macrophages,
granulocytes, and dendritic cells (Kupffer cells) can migrate
to injured islets and contribute to their destruction (14).
Although injured islets do not necessarily contribute to the
development of alloreactivity (14), it has been shown that
both humeral and cellular adaptive allogenic immune
responses in the liver are involved in human islet graft re-
jection.
An increased frequency of antidonor-speciﬁc cytotoxic
T-cell precursors as well as pretransplant HLA sensiti-
zation and donor-speciﬁc antibodies are associated with
accelerated graft failure (3) (Fig. 5). Bosi et al. (15)
demonstrate a correlation between newly formed auto-
antibodies and accelerated risk of graft failure. However,
islet graft failure can also occur in the absence of in-
creased autoantibody, suggesting that the autoimmune
humeral response is not a crucial factor in islet graft fail-
ure. The presence of the pretransplant autoreactive cells
are considered to be more important. When the activity of
T-cells speciﬁc for islet autoantigens such as insulinoma-
associated protein 2 (IA2) and glutamate decarboxylase
(GAD) (16) is high, grafts are more likely to fail. If im-
munosuppression is effective, recipients will develop an
allograft-speciﬁc cytokine proﬁle skewed toward a T-helper
2 or regulatory phenotype.
Maintaining a regulatory phenotype in the liver might be
complex because the liver contains abundant NKT cells
FIG. 1. The principal difference between human and rodent intraportal islet infusion. Rodent islets are relatively large in comparison with the liver
veins. Therefore, these islets are instantly trapped in liver veins and cause local thrombosis, which results in vascularization. Human islets are
relatively small in proportion to the veins. In order to be trapped and induce vascularization, these islets adhere to blood clots that adhere to the
walls of the liver veins.
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(17). A special feature of the NKT cell subset is that it
coexpresses invariant T-cell receptors and NK cell–related
surface markers. Activated NKT cells produce large
amounts of cytokines such as IL-4, IL-10, IL-5, IFN-g and
TNF-b. These cytokines activate CD4 T-helper 1 cells,
CD8 cytotoxic T-cells, and cells of the innate immune
system (17). This immune response may be responsible
for signiﬁcant damage to the islets, as well as promoting
efﬁcient immune recognition and even allograft islet re-
jection (17).
High concentrations of immunosuppressive drugs.
Islets are exposed to relatively high concentrations of im-
munosuppressive drugs in the liver (3,14). However, it is not
clear whether this high concentration is beneﬁcial or det-
rimental to islet survival. The high concentrations of im-
munosuppressive drugs could be toxic and may interfere
FIG. 2. Islet loss by hypoxia. The low oxygen tension of the liver parenchyma enhances hypoxia (4). Hypoxia triggers the innate immune system
resulting in the release of the cytokines IFN-g, TNF-a, and IL-1b, which are harmful for islets (7). Furthermore, b-cells undergo an epithelial-to-
mesenchymal transition under hypoxic conditions. This transition is provoked by HIF-1a activation, which mediates Twist expression (8). Twist
expression contributes to the development of ﬁbrosis.
FIG. 3. IBMIR. This inﬂammatory reaction is elicited by direct contact between islets and blood (9). A: Islets express tissue factor (TF), which
activates a thrombotic reaction. B: Thrombin forms ﬁbrin capsules around the islets and activates platelets, which bind to the islets. C: Activated
platelets upregulate P-selectin markers resulting in the inﬁltration of neutrophils and monocytes. Also, thrombin stimulates the activation of
granulocytes and monocytes. In addition, platelet-activating factor produced by portal endothelial cells and complement products serve as che-
moattractants for more neutrophils and macrophages. Tissue factor, ﬁbrin, and ﬁbrinogen may directly affect macrophages.
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with angiogenesis and impair b-cell proliferation (3,14). On
the other hand, the high levels could more effectively protect
the islets from undesired responses from the immune sys-
tem (14). More studies are needed to determine whether the
high concentrations are beneﬁcial or detrimental to func-
tional islet survival. Besides immunosuppressive drugs,
islets are also exposed to other circulating toxins, which are
detoxiﬁed by the liver and could have a detrimental effect.
FIG. 4. Nonspeciﬁc, innate, and adaptive immune responses against human islet allografts in the liver. Nonspeciﬁc immunological responses such
as IBMIR have been well-characterized but human islets provoke more responses in the immediate posttransplant period. After isolation, human
islets express MMP1 and FN1, which are involved in tissue remodeling, adhesion, and cell migration (11). Also the proinﬂammatory cytokines
IL-1b and IL-8 are expressed as well as the chemotactic chemokines CXCL2, CCL2, CXCL12, CXCL1, CXCL6, and CCL28 that induce neutrophil
and monocyte recruitment (11). These—but also other proinﬂammatory mediators such as MIF, TNF, IFN-g, and MCP-1—have been shown to
inﬂuence graft survival by activating the innate immune system (13,14). In addition, human islets express ATF3, a transcription factor that plays
a role in b-cell apoptosis (14).
FIG. 5. Adaptive responses against human islet allografts in the liver. Pretransplant autoantibodies and autoreactive T-cells are triggered by
antigens such as IA2, GAD, and insulin (15,16). HLA is recognized by alloreactive cytotoxic T-cell precursors and antibodies (3). Furthermore, the
high amount of NKT cells in the liver with alloreactivity can expedite the allograft rejection process via nonclassical MHC molecules such as CD1d.
Secretion of IL-4, IL-10, IL-5, IFN-g and TNF-b activates the CD4 T helper 1 cells, CD8 cytotoxic T-cells leading to graft failure (17). Notably, NK
and NKT cells are not suppressed by the currently applied immunosuppressants.
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OTHER TRANSPLANTATION SITES
The human liver may not be the most optimal site for islet
transplantation. Although other sites have been studied to
avoid liver-associated problems, many of these are not ac-
ceptable alternatives. Due to IBMIR, several extravascular
sites (such as the pancreas [18], gastric submucosa [19], stri-
ated muscle [20], peritoneum [21], omentum [22], bone mar-
row [23], kidney capsule [24], lymph node [25], spleen [26])
and a few immunoprivileged sites (27) (like the anterior eye
chamber, the testis, and the thymus) have been considered as
potential islet transplantation sites. These sites are discussed
below in terms of their potential clinical application.
Theoretically, the pancreas is an attractive site for islet
transplantation because it provides optimal oxygen ten-
sion and allows insulin secretion in physiologically rele-
vant areas (18). Rodent and canine studies show adequate
glucose metabolism and minimal inﬂammatory and ﬁbrotic
responses after intrapancreatic islet transplantation (18).
However, islet transplantation into the pancreas is an in-
vasive procedure that carries a high risk of pancreatitis
and recurrence of autoimmunity (27). Therefore, the pan-
creas is not likely to be an acceptable alternative to the
human liver.
Animal experiments also show adequate islet function
after grafting in the gastric submucosa (19). The sub-
mucosal space provides rapid revascularization because of
its dense vascular network. It also provides the advantage
of easy access by endoscopy, and it simulates physiologic
glucose sensing (19). Outcomes of animal models however
are not yet translated to the clinic. Although it might be an
attractive site, human studies are needed.
Striated muscle provides high vascularization, easy ac-
cessibility, monitoring with routine biopsies, and minimal
surgical complications. This site has been tested in the clinic
for islet autotransplantation after chronic pancreatitis (28).
Studies of intramuscular islet transplantation show improved
revascularization compared with liver transplantation as
well as sufﬁcient oxygen tension (20). However, central ne-
crosis and extensive ﬁbrosis occurred that ultimately resul-
ted in graft failure (20).
The greater omentum seems an ideal transplantation site
because of its adequate arterial supply, portal drainage,
easy accessibility, and large vascular network. Both
transplantation in the peritoneum and the omental pouch
reversed hyperglycemia in animal models, but high num-
bers of islets were needed to achieve these results because
of the considerable loss of islets (21,22). This makes clin-
ical transplantation in the peritoneum or omentum, where
scarce donors are applied, unrealistic.
The bone marrow has received much attention during
recent years. The bone marrow is relatively easily accessible
and well vascularized. Rodent studies showed efﬁcient and
safe islet transplantation into bone marrow (23). No human
data are available, but a clinical pilot is ongoing in Italy (27).
Islet transplantation under the kidney capsule of animals
results in normoglycemia despite the relatively poor blood
and oxygen supply (24). However, the kidney capsule
remains clinically irrelevant as a transplantation site due to
the required invasive surgery, the limited space for the
transplant mass needed for reversion of diabetes, and the
possible induction of diabetic nephropathy (27).
Recently, Komori et al. (25) showed in mice that the lymph
node might be an efﬁcacious site for islet transplantation.
This site is easily accessible with minimal invasive tech-
niques. The dense vasculature of lymph nodes provides direct
access to nutrients and oxygen. However, the lymph node
is the center of the immune system and contains large
numbers of immune cells such as T and B cells. These
packed lymphocytes could therefore create hurdles for
clinical application.
Islet transplantation into the spleen has been shown to
reverse diabetes in animal models (26). The spleen pro-
vides adequate vascularization and insulin distribution, but
the spleen also contains large numbers of lymphocytes and
is also associated with a high risk of bleeding. These fac-
tors imply barriers for clinical application.
To prevent graft rejection induced by the immune system,
several immunoprivileged sites have been investigated (27).
Successful islet transplantation is possible in the anterior
eye chamber, testis, and thymus. However, these sites are
not suitable in clinical settings due to the vitality and small
size of the organs (27).
Despite successful animal experiments and the promising
futures for some clinical trials with other transplantation
sites, an optimal islet transplantation site has yet to be de-
ﬁned. There are multiple requirements for such an optimal
site: 1) minimal activation of the immune system, 2) rapid
revascularization, 3) mimicking of physiological glucose
sensing and facilitation of insulin release, and 4) easy ac-
cessibility for minimal invasive surgery and follow-up of the
transplant (27). A site with these characteristics will provide
an optimal environment for islet survival and functioning.
An engineered transplantation site for pancreatic
islets. The human body does not contain an environment
that meets the ideal requirements for islet transplantation.
There are two strategies that can therefore be pursued: 1)
modify an existing organ such that it meets the require-
ments or 2) engineer an alternative transplantation site.
Modifying an organ is not without risks because it might
interfere with normal functioning. The other approach—
engineering a transplantation site for pancreatic islets—was
proposed as early as 1996 (29). Islets can be implanted
under the skin or in the peritoneal cavity with solid support
devices. These devices contain a collagen IV network to-
gether with acidic ﬁbroblast growth factor or an osmotic
pump containing vascular endothelial growth factor. This
was effective in inducing capillary ingrowth for rapid islet
revascularization. Isogenic transplanted islets have been
shown to survive and function for prolonged periods of time
in the devices. However, when compared with islets in the
naïve pancreas, glucose-induced insulin responses were
reduced, which was associated with the loss of islets in the
immediate period after implantation (30).
In the past few years a new concept has been introduced
to minimize the loss of islets by ischemia or undesired im-
mune responses. This concept involves “seeding” individual
islets onto three-dimensional scaffolds. The scaffolds are
made of biopolymer ﬁbers that provide a three-dimensional
support structure for the islets and mimic the pancre-
atic microenvironment (31) (Fig. 6). Islets engraft more
effectively in three-dimensional structures than in two-
dimensional structures, and the scaffold improves viability
by promoting cell adherence and nutrient diffusion
thereby increasing islet survival immediately after trans-
plantation. This scaffolding also allows for local adminis-
tration of immunosuppression to suppress the speciﬁc
immune responses directed against the islets. In addition,
a polymer scaffold prevents direct exposure to blood in
the ﬁrst few weeks after transplantation thereby attenu-
ating an inﬂammatory response but not creating an im-
mune barrier (31). These islet scaffolds have been shown
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to be efﬁcacious in animal studies. Diabetic rodents be-
came normoglycemic shortly after transplantation with an
islet-containing polymer device (31). However, these
results have not yet been translated into clinical practice.
Essence of an extracellular matrix. Surprisingly, the
immediate microenvironment–the role of the extracellular
matrix (ECM)–has not received much attention in the se-
lection of an adequate islet transplantation site. However,
many studies illustrate the necessity of an adequate ECM
for optimal survival of islets (32). The composition of the
pancreatic ECM is very speciﬁc and probably serves as
a reservoir for mandatory growth factors that potentiate
tissue repair and homeostasis (32). Islet survival increases
when islets are cultured in ECM proteins such as ﬁbro-
nectin, collagen IV, or laminin (33). Also the synthetic RGD
sequence (argenin-glycin-aspartic), which is present in
many ECM molecules, enhances b-cell survival by de-
creasing the sensitivity to apoptosis (33). Combining this
with collagen IV, an ECM component abundantly present
in blood vessels, may at the same time facilitate re-
vascularization (29). A functional ECM might contribute to
faster recovery from the isolation stress because many
ECM components function as anchors for growth factors
that contribute to tissue recovery. However, this cannot
be done in too high quantities because collagen IV not only
enhances islets survival, it can also decrease islet func-
tionality by diminishing glucose-induced insulin re-
sponses (34). Many ECM-derived peptide fragments (peptide
fragments located on laminin a-1 chain: RGD, IKLLI, and
IKVAV; laminin g-1 chain: LRE; laminin b-1 chain located:
PDSGR and YIGSR; and type 1 collagen a 1(I)-CB3 frag-
ment: DGEA) and growth factors have been shown to
enhance b-cell survival and function (35) and might even
lead to a signiﬁcant reduction in the amount of islets and
donors required to cure diabetes. Such reductions require
further consideration because they might be important for
advancing the islet transplant ﬁeld. The overall shortage
of donor organs remains a major challenge, particularly
for the widespread use of islet transplantation. Multiple
donors are required, and the islet yield and success rate
are determined by factors such as the health status of the
donor, the condition of the pancreas, the mode of transport,
and the quality of the isolation procedure (36). Due to the
low number of donors, only a small number of carefully
selected patients are eligible for islet transplantation. This
may change if we are able to engineer a site that not
only meets the requirements described above, but also
is more efﬁcacious than conventional sites because it
reduces the number of required islets. We recently showed
that growth hormone–releasing agonists may be one such
factor (37).
CHALLENGES IN ENGINEERING AN ARTIFICIAL
TRANSPLANTATION SITE FOR PANCREATIC ISLETS
Although the principal applicability of an artiﬁcial trans-
plantation site for pancreatic islets has been shown (38),
FIG. 6. A three-dimensional biopolymeric scaffold for islet transplantation. This polymer device can be placed in the peritoneal cavity. The device
provides a three-dimensional support structure for the islets and mimics the pancreatic microenvironment. Furthermore, by adding ECM proteins
such as collagen IV, ﬁbronectin or laminin, or speciﬁc components of these ECM components, islet survival can be stimulated (31,33). The ECM
also serves as depot for angiogenic and growth factors such as VEGF, which supports revascularization of the islets.
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there are a number of critical items that remain to be solved
before application in humans can be considered. In pre-
vious studies from our group, we used polytetraﬂuoro-
ethylene as a scaffold (30). Although inert, it was associated
with strong ﬁbrotic responses. This was solved by
implanting the devices 4 weeks before the introduction of
the islets. However, the introduction of the islets required
puncturing and damaging of the device and immune acti-
vation. In order to meet the requirement of minimal acti-
vation of the immune system, new scaffolds should be
developed. The success of any polymer as scaffold material
depends on several properties including induction of severe
inﬂammation and foreign body responses, permeability, and
revascularization. The polymers should allow nonlaborious
and easy engineering into different geometries, and ideally,
should already be approved for human application.
A number of polymers have favorable properties to
serve as scaffolding material for an artiﬁcially engineered
islet transplantation site. The polymer poly(DL-lactide-
cocaprolactone), commercially available as Neurolac, is
one example (39). Neurolac is already U.S. Food and Drug
Administration (FDA)/CE (European conformity) approved
for the repair of small peripheral nerve defects (39). It
degrades over 24 months by hydrolysis, and the degrada-
tion products are nonacidic (40). However, some animal
and clinical studies reported a foreign body response
(39,40), which should be tested for its compatibility with
the functional survival of islets.
Polyactive is another candidate. This is a copolymer of
poly(ethylene oxide terephtalate) (PEOT) and poly(butyl-
ene terephtalate) (PBT) and is FDA/CE approved for or-
thopedic medical devices (41). Polyactive is a thermoplastic
polymer (42) that has mechanical and degradation proper-
ties that can be controlled by the PEOT/PBT weight ratio
(42). The degradation products after hydrolysis are non-
acidic and do not induce a systemic immune response (43).
In animal studies, Polyactive was shown to be surrounded
by capillary-rich granulation suggesting that the polymer
itself contributes to vascularization (43). Although Poly-
active triggered the inﬂux of immune cells at the implanta-
tion site in animal studies (43), application of the copolymer
in the clinic was not associated with any side effects, and no
inﬂammatory or abnormal cellular response was found 1
year after implantation (44).
Polysulfone is also a promising candidate polymer that
has been shown to be compatible with the survival of islets
in animal models (45). This polymer is FDA approved as
dialyzer, is histocompatible, associated with low cytotox-
icity (46), and provides a matrix for cell growth and cell
attachment. Histological analysis revealed that many blood
vessels were formed on the surface of Polysulfone. How-
ever, a foreign body response was also observed (45).
Whether this interferes with islet function has yet to be
determined.
The responses against biomaterials are highly dependent
on the site of implantation (47). Most studies have been
performed in the subcutaneous tissue and the peritoneal
cavity. Both sites qualify as transplantation sites for islets
because they are easily accessible. A device can be placed
and ﬁxed on the abdominal wall or be ﬁxed in the skin. In
both rodents and pigs, the use of devices has shown some
success (48,49), but whether this can be translated to
humans depends in part on the size of the scaffold. The
average islet diameter is 150 mm. Although the whole islet
graft is only 1 inch in size, it should probably be seeded
with more space between the islets in a three-dimensional
polymeric device to allow rapid ingrowth of vessels and to
avoid ischemia during revascularization. Exact calculations
of the ideal size are not yet available. A three-dimensional
scaffold is expected to facilitate revascularization to im-
prove oxygenation, nutrient access, glucose sensing, and
insulin release shortly after islet transplantation. As outlined
above, the scaffold should contain ECM components and
growth factors to enhance the efﬁcacy of the site. What this
matrix should look like has yet to be determined.
Notably, an artiﬁcial transplantation site for pancreatic
islets may be applicable not only for free islets but also for
islets encapsulated in immunoprotective membranes (50).
Encapsulated islets are usually transplanted as free-ﬂoating
grafts in the peritoneal cavity (29). This interferes with the
ability to retrieve the graft and to predict the distance of
the islets to the blood vessels. Artiﬁcial sites may solve
both problems and may also contribute to prolongation of
graft longevity which, at present, is a major obstacle for
clinical application of immunoisolated islets.
CONCLUSION
A biopolymeric scaffold allows the creation of a novel ec-
topic transplantation site for islets. Such a novel trans-
plantation site is needed because the liver does not provide
an optimal environment for islet engraftment, and alterna-
tive sites also seem to be insufﬁcient. This novel engineered
site should meet all the requirements for an optimal trans-
plantation site–minimal induction of the immune system,
rapid revascularization, adequate glucose sensing and in-
sulin release, and easy accessibility. This approach may
lead to a signiﬁcant reduction of the loss of islets because
direct contact with blood and islets is prevented. Further-
more, because the site is easily accessible, it may allow for
the application of local, tailored immunosuppression, which
has recently been suggested as a necessary tool to manage
the complex and individual differences in immune re-
sponses (14). However, the characteristics of several
biopolymers should be investigated further to ensure that
the polymer does not interfere with islet function or induce
toxicity for islets. Engineering of a novel transplantation
site is immensely important for the successful treatment of
type 1 diabetic patients.
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